^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).
Published date:
05/26/2022
Excerpt:
ULI-EAP-100 (NCT04566393) is an ongoing intermediate expanded access protocol (EAP) that offers ulixertinib to US patients with advanced solid tumors harboring MAPK pathway alterations...Four pts attained clinical benefit including BRAF V600E PDAC and glioblastoma pts on monotherapy for 413 and 128 days, respectively.
DOI:
10.1200/JCO.2022.40.16_suppl.e15101
Trial ID:
